Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent comorbidity in psoriasis and a risk factor for cardiovascular disease, a major cause of death among patients with psoriasis. Although the exact causal relationship between these two disorders is not fully established, the underlying pathophysiology linking psoriasis and MetS seems to involve overlapping genetic predispositions and inflammatory pathways. Dysregulation of the IL‐23/Th‐17 immune signalling pathway is central to both pathologies and may be key to promoting susceptibility to metabolic and cardiovascular diseases in individuals with and without psoriasis. Thus, biological treatments for psoriasis that interrupt these signals could both reduce the psoriatic inflammatory burden and also lessen the risk of developing atherosclerosis and cardiometabolic diseases. In support of this hypothesis, improvement of skin lesions was associated with improvement in vascular inflammation in recent imaging studies, demonstrating that the beneficial effect of biological agents goes beyond the skin and could help to prevent cardiovascular disease. This review will summarize current knowledge on underlying inflammatory mechanisms shared between psoriasis and MetS and discuss the most recent clinical evidence for the potential for psoriasis treatment to reduce cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
Steinthorsdottir, V., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Jonsdottir, T., Walters, G. B., Styrkarsdottir, U., Gretarsdottir, S., Emilsson, V., Ghosh, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2043 · Cited by 1,072
Mehta, N. N., Azfar, R. S., Shin, D. B., Neimann, A. L., Troxel, A. B., & Gelfand, J. M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp567 · Cited by 706
Wolf, N., Quaranta, M., Prescott, N. J., Allen, M., Smith, R., Burden, A. D., Worthington, J., Griffiths, C. E. M., Mathew, C. G., Barker, J. N., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053595 · Cited by 171
Yang, Z.-S., Lin, N.-N., Li, L., & Li, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8560-9 · Cited by 123
Cited by
Macrophage INSIG1 deficiency drives psoriasiform dermatitis via the SREBP2-STAT1 axis
Li, X., Zang, Y., Li, X., Sheng, T., Liu, S., Chen, L., Xu, X., Wang, L., Long, R., Zhang, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73278-8 · Cited by 1
Metadata
- Authors
- Wu, J. J., Kavanaugh, A., Lebwohl, M. G., Gniadecki, R., & Merola, J. F.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2022-03-14
- Volume
- 36
- Issue
- 6
- Pages
- 797-806
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W4214807866
- Cited by
- 199
- References
- 7
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.